Neoantigen?based vaccines as a promising strategy in cancer immunotherapeutics

The development of cancer vaccines is based on the premise that tumor cells are potentially targetable by host immunity through effective presentation tumor-associated antigens to reactive T-cell populations. Vaccine efficacy may be limited functional properties effector including lack high-affinity T target self-antigens. In contrast, neoantigens arise from tumor-specific mutational events generate epitopes seen as foreign immunity. As such, neoantigen-targeted vaccination provides a high level specificity, promotes greater function, and minimizes off-target toxicities. Next-generation sequencing high-throughput computational algorithms have allowed for identification in solid hematologic malignancies. generation involves screening potential HLA restriction reactivity repertoire. Early phase studies demonstrated feasibility vaccine production resultant potent immunologic responses. clinical impact neoantigen its incorporation into combinatorial immunotherapeutic strategies currently being explored.